Immune checkpoint blockade is a promising approach in cancer immunotherapy that enhances antitumor immunity by inhibiting pathways that suppress T cell activity. These checkpoints, which include proteins like CTLA4 and PD1, are crucial for maintaining self-tolerance and regulating immune responses. Tumors can exploit these pathways to evade immune detection, making their blockade a potential therapeutic strategy. Antibodies targeting these checkpoints, such as anti-CTLA4 and anti-PD1, have shown clinical efficacy in various cancers, including melanoma. Anti-CTLA4 therapy was the first to demonstrate survival benefits in advanced melanoma patients, leading to FDA approval. Anti-PD1 therapy has also shown promise, with clinical trials indicating durable responses in multiple tumor types. The mechanisms of action of these therapies involve enhancing T cell activation and reducing immune suppression. However, they can cause immune-related toxicities, which require careful management. Understanding the expression and regulation of immune checkpoint proteins in tumors is essential for optimizing therapeutic strategies. Current research focuses on identifying biomarkers to predict response to checkpoint inhibitors and exploring combination therapies to enhance antitumor immunity. The development of new checkpoint inhibitors and the refinement of existing ones continue to advance the field of cancer immunotherapy.Immune checkpoint blockade is a promising approach in cancer immunotherapy that enhances antitumor immunity by inhibiting pathways that suppress T cell activity. These checkpoints, which include proteins like CTLA4 and PD1, are crucial for maintaining self-tolerance and regulating immune responses. Tumors can exploit these pathways to evade immune detection, making their blockade a potential therapeutic strategy. Antibodies targeting these checkpoints, such as anti-CTLA4 and anti-PD1, have shown clinical efficacy in various cancers, including melanoma. Anti-CTLA4 therapy was the first to demonstrate survival benefits in advanced melanoma patients, leading to FDA approval. Anti-PD1 therapy has also shown promise, with clinical trials indicating durable responses in multiple tumor types. The mechanisms of action of these therapies involve enhancing T cell activation and reducing immune suppression. However, they can cause immune-related toxicities, which require careful management. Understanding the expression and regulation of immune checkpoint proteins in tumors is essential for optimizing therapeutic strategies. Current research focuses on identifying biomarkers to predict response to checkpoint inhibitors and exploring combination therapies to enhance antitumor immunity. The development of new checkpoint inhibitors and the refinement of existing ones continue to advance the field of cancer immunotherapy.